Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 4, Pages 669
Publisher
MDPI AG
Online
2021-02-09
DOI
10.3390/cancers13040669
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Opportunities for Small Molecules in Cancer Immunotherapy
- (2020) Sabina Y. van der Zanden et al. TRENDS IN IMMUNOLOGY
- Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates
- (2020) Dennis J. Worm et al. Peptide Science
- Properties of FDA-approved small molecule protein kinase inhibitors
- (2019) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index
- (2019) Steven Coats et al. CLINICAL CANCER RESEARCH
- Illuminating the Onco-GPCRome: Novel G protein–coupled receptor-driven oncocrine networks and targets for cancer immunotherapy
- (2019) Victoria Wu et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application
- (2019) Sikandar Hayat Khan Molecular Therapy-Nucleic Acids
- Peptide‐Driven Targeted Drug‐Delivery System Comprising Turn‐On Near‐Infrared Fluorescent Xanthene–Cyanine Reporter for Real‐Time Monitoring of Drug Release
- (2019) T. M. Ebaston et al. ChemMedChem
- Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
- (2019) Daphné Morel et al. Nature Reviews Clinical Oncology
- An omics perspective on drug target discovery platforms
- (2019) Jussi Paananen et al. BRIEFINGS IN BIOINFORMATICS
- Natural DNA Intercalators as Promising Therapeutics for Cancer and Infectious Diseases
- (2019) Martyna Godzieba et al. CURRENT CANCER DRUG TARGETS
- CRISPR screening identifies WEE1 as a combination target for standard chemotherapy in malignant pleural mesothelioma
- (2019) Duo Xu et al. MOLECULAR CANCER THERAPEUTICS
- A view on drug resistance in cancer
- (2019) Neil Vasan et al. NATURE
- Synthetic lethality as an engine for cancer drug target discovery
- (2019) Alan Huang et al. NATURE REVIEWS DRUG DISCOVERY
- Genome-wide CRISPR/Cas9 library screening identified PHGDH as a critical driver for Sorafenib resistance in HCC
- (2019) Lai Wei et al. Nature Communications
- Drug-induced PD-L1 expression and cell stress response in breast cancer cells can be balanced by drug combination
- (2019) Yosi Gilad et al. Scientific Reports
- Molecular Targeting Therapy against EGFR Family in Breast Cancer: Progress and Future Potentials
- (2019) Amaia Eleonora Maennling et al. Cancers
- Fluorescent Reporters for Drug Delivery Monitoring
- (2019) Leonid Patsenker et al. ISRAEL JOURNAL OF CHEMISTRY
- PARP inhibitors in breast cancer: Bringing synthetic lethality to the bedside
- (2018) Anita A. Turk et al. CANCER
- Resistance to Antibody–Drug Conjugates
- (2018) Sara García-Alonso et al. CANCER RESEARCH
- How CRISPR is transforming drug discovery
- (2018) Andrew Scott NATURE
- Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
- (2018) Alan Ashworth et al. Nature Reviews Clinical Oncology
- Cancer-targeted delivery systems based on peptides
- (2018) Theodora Chatzisideri et al. Future Medicinal Chemistry
- ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).
- (2018) David S. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-ligand 1 Signaling Pathway
- (2018) Tianyu Wang et al. JOURNAL OF MEDICINAL CHEMISTRY
- Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
- (2018) Ami N. Shah et al. ONCOLOGIST
- Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials
- (2018) Rafael Caparica et al. BREAST CANCER RESEARCH AND TREATMENT
- Design, Synthesis, and Biological Evaluation of Polyaminocarboxylate Ligand-Based Theranostic Conjugates for Antibody-Targeted Cancer Therapy and Near-Infrared Optical Imaging
- (2018) Siyuan Ren et al. ChemMedChem
- Polymer–drug conjugate therapeutics: advances, insights and prospects
- (2018) Iriny Ekladious et al. NATURE REVIEWS DRUG DISCOVERY
- CRISPR knockout screening identifies combinatorial drug targets in pancreatic cancer and models cellular drug response
- (2018) Karol Szlachta et al. Nature Communications
- Discovery of potent molecular chimera (CM358) to treat human metastatic melanoma
- (2017) Y. Gilad et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Current State of Peptide Drug Discovery: Back to the Future?
- (2017) Antoine Henninot et al. JOURNAL OF MEDICINAL CHEMISTRY
- Emerging functions of the EGFR in cancer
- (2017) Sara Sigismund et al. Molecular Oncology
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- Strategies and challenges for the next generation of antibody–drug conjugates
- (2017) Alain Beck et al. NATURE REVIEWS DRUG DISCOVERY
- Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
- (2017) Derek McCulloch et al. OncoTargets and Therapy
- Origins of Combination Therapy for Tuberculosis: Lessons for Future Antimicrobial Development and Application
- (2017) Christopher A. Kerantzas et al. mBio
- Acute lymphoblastic leukemia: a comprehensive review and 2017 update
- (2017) T Terwilliger et al. Blood Cancer Journal
- Orthogonal Cysteine Protection Enables Homogeneous Multi-Drug Antibody-Drug Conjugates
- (2016) Matthew R. Levengood et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Development of Solid-Phase Site-Specific Conjugation and Its Application toward Generation of Dual Labeled Antibody and Fab Drug Conjugates
- (2016) Sujiet Puthenveetil et al. BIOCONJUGATE CHEMISTRY
- Dual-drug RGD conjugates provide enhanced cytotoxicity to melanoma and non-small lung cancer cells
- (2016) Y. Gilad et al. BIOPOLYMERS
- Molecular Pathways: Targeting Steroid Receptor Coactivators in Cancer
- (2016) David M. Lonard et al. CLINICAL CANCER RESEARCH
- Small-molecule kinase inhibitors: an analysis of FDA-approved drugs
- (2016) Peng Wu et al. DRUG DISCOVERY TODAY
- Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy
- (2016) Christina Pfirschke et al. IMMUNITY
- Mechanisms of Resistance to Antibody–Drug Conjugates
- (2016) Frank Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- Cornerstones of CRISPR–Cas in drug discovery and therapy
- (2016) Christof Fellmann et al. NATURE REVIEWS DRUG DISCOVERY
- Dual modification of biomolecules
- (2016) Antoine Maruani et al. ORGANIC & BIOMOLECULAR CHEMISTRY
- Combination Chemotherapy of Solid Tumors: An American-Italian Collaboration: A Celebration of the work of Gianni Bonadonna
- (2016) Vincent T. DeVita et al. TUMORI
- Combination Chemotherapy of Solid Tumors: An American-Italian Collaboration: A Celebration of the work of Gianni Bonadonna
- (2016) Vincent T. DeVita et al. TUMORI JOURNAL
- Development and Evaluation of a Fluorescent Antibody-Drug Conjugate for Molecular Imaging and Targeted Therapy of Pancreatic Cancer
- (2016) Steve Knutson et al. PLoS One
- Site-Specific Dual Antibody Conjugation via Engineered Cysteine and Selenocysteine Residues
- (2015) Xiuling Li et al. BIOCONJUGATE CHEMISTRY
- Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future
- (2015) Lieping Chen et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhancing Accumulation and Penetration of HPMA Copolymer–Doxorubicin Conjugates in 2D and 3D Prostate Cancer Cells via iRGD Conjugation with an MMP-2 Cleavable Spacer
- (2015) Zheng-Hong Peng et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Tumor Cells Chronically Treated with a Trastuzumab-Maytansinoid Antibody-Drug Conjugate Develop Varied Resistance Mechanisms but Respond to Alternate Treatments
- (2015) F. Loganzo et al. MOLECULAR CANCER THERAPEUTICS
- CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
- (2015) R. Chen et al. MOLECULAR CANCER THERAPEUTICS
- A plug-and-play approach to antibody-based therapeutics via a chemoselective dual click strategy
- (2015) Antoine Maruani et al. Nature Communications
- “Switch off/switch on” regulation of drug cytotoxicity by conjugation to a cell targeting peptide
- (2014) Yossi Gilad et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Recent advances in small organic molecules as DNA intercalating agents: Synthesis, activity, and modeling
- (2014) Antonio Rescifina et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- The Leukemias: A Half-Century of Discovery
- (2014) Emil J. Freireich et al. JOURNAL OF CLINICAL ONCOLOGY
- Combination of Small Molecule Prodrug and Nanodrug Delivery: Amphiphilic Drug–Drug Conjugate for Cancer Therapy
- (2014) Ping Huang et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
- (2014) Roger Stupp et al. LANCET ONCOLOGY
- Identification of Verrucarin A as a Potent and Selective Steroid Receptor Coactivator-3 Small Molecule Inhibitor
- (2014) Fei Yan et al. PLoS One
- From old alkylating agents to new minor groove binders
- (2013) Stéphane Puyo et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Docking Studies on DNA Intercalators
- (2013) Yocheved Gilad et al. Journal of Chemical Information and Modeling
- Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
- (2013) Francesco Lo-Coco et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety
- (2013) L. Zhu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- A 50-Year Journey to Cure Childhood Acute Lymphoblastic Leukemia
- (2013) Ching-Hon Pui et al. SEMINARS IN HEMATOLOGY
- Drugging Topoisomerases: Lessons and Challenges
- (2012) Yves Pommier ACS Chemical Biology
- The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer
- (2012) Madhu S. Kumar et al. CELL
- Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies
- (2012) Michael Steckel et al. CELL RESEARCH
- Decline in the Use of Anthracyclines for Breast Cancer
- (2012) Sharon H. Giordano et al. JOURNAL OF CLINICAL ONCOLOGY
- Topoisomerase as target for antibacterial and anticancer drug discovery
- (2012) Muthu K. Kathiravan et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Targeted drug delivery for cancer therapy: the other side of antibodies
- (2012) Michael A Firer et al. Journal of Hematology & Oncology
- Functional genomics identifies therapeutic targets for MYC-driven cancer
- (2012) M. Toyoshima et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cilengitide: The First Anti-Angiogenic Small Molecule Drug Candidate. Design, Synthesis and Clinical Evaluation
- (2011) Carlos Mas-Moruno et al. Anti-Cancer Agents in Medicinal Chemistry
- From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia
- (2011) S.-J. Chen et al. BLOOD
- Sulfur mustard toxicity: History, chemistry, pharmacokinetics, and pharmacodynamics
- (2011) Kamyar Ghabili et al. CRITICAL REVIEWS IN TOXICOLOGY
- Somatostatin-Dopamine Chimeras: A Novel Approach to Treatment of Neuroendocrine Tumors
- (2011) M. Culler HORMONE AND METABOLIC RESEARCH
- First Use of Intravenous Chemotherapy Cancer Treatment: Rectifying the Record
- (2011) John E. Fenn et al. JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- The status of platinum anticancer drugs in the clinic and in clinical trials
- (2010) Nial J. Wheate et al. DALTON TRANSACTIONS
- Arsenic trioxide as first-line treatment for acute promyelocytic leukemia
- (2009) Lily Leu et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Targeting Bone Metastases with a Bispecific Anticancer and Antiangiogenic Polymer-Alendronate-Taxane Conjugate
- (2009) Keren Miller et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Notoriety to respectability: a short history of arsenic prior to its present day use in haematology
- (2009) Derek Doyle BRITISH JOURNAL OF HAEMATOLOGY
- A Genome-wide RNAi Screen Identifies Multiple Synthetic Lethal Interactions with the Ras Oncogene
- (2009) Ji Luo et al. CELL
- Translation of the Philadelphia chromosome into therapy for CML
- (2008) B. J. Druker BLOOD
- A History of Cancer Chemotherapy
- (2008) Vincent T. DeVita et al. CANCER RESEARCH
- Nucleoside analogs: molecular mechanisms signaling cell death
- (2008) B Ewald et al. ONCOGENE
- An engineered selenocysteine defines a unique class of antibody derivatives
- (2008) T. Hofer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started